Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum

The level of anti-SARS-CoV-2 neutralizing antibodies (NAb) is an indispensable reference for evaluating the acquired protective immunity against SARS-CoV-2. Here, we established an ultrabright nanoparticles-based lateral flow immunoassay (LFIA) for one-step rapid semi-quantitative detection of anti-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomaterials 2022-09, Vol.288, p.121694-121694, Article 121694
Hauptverfasser: Bian, Lun, Li, Zhaoyue, He, An, Wu, Biru, Yang, Hui, Wu, Yingsong, Hu, Fang, Lin, Guanfeng, Zhang, Deqing
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 121694
container_issue
container_start_page 121694
container_title Biomaterials
container_volume 288
creator Bian, Lun
Li, Zhaoyue
He, An
Wu, Biru
Yang, Hui
Wu, Yingsong
Hu, Fang
Lin, Guanfeng
Zhang, Deqing
description The level of anti-SARS-CoV-2 neutralizing antibodies (NAb) is an indispensable reference for evaluating the acquired protective immunity against SARS-CoV-2. Here, we established an ultrabright nanoparticles-based lateral flow immunoassay (LFIA) for one-step rapid semi-quantitative detection of anti-SARS-CoV-2 NAb in vaccinee's serum. Once embedded in polystyrene (PS) nanoparticles, the aggregation-induced emission (AIE) luminogen, AIE490, exhibited ultrabright fluorescence due to the rigidity of PS and severe inhibition of intramolecular motions. The ultrabright AIE490-PS nanoparticle was used as a fluorescent marker of LFIA. Upon optimized conditions including incubation time, concentrations of coated proteins and conjugated nanoparticles, amounts of antigens modified on the surface of nanoparticles, dilution rate of serum samples, and so on, the ultrabright nanoparticles-based LFIA could accurately identify 70 negative samples and 63 positive samples from human serum (p 
doi_str_mv 10.1016/j.biomaterials.2022.121694
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9360774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0142961222003349</els_id><sourcerecordid>35977850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c553t-ab25dbfc923d57f3146fa94400340a8125ca4358617d4d4ba7485e42c21012453</originalsourceid><addsrcrecordid>eNqNkUuLFDEUhYMoTjv6FyS4rzZJJfVwIQw9vmBAcBy3IZXc6r5NKmmSqpFx5z83besw7lyFcO85JzkfIa84W3PGm9f79YBxMjMkND6vBRNizQVvevmIrHjXdpXqmXpMVoxLUfUNF2fkWc57Vu5MiqfkrFZ923aKrcjPGz8nMyTc7mYaTIgHk2a0HipvBvDgqD8GGU9HH79TnKYlRJOzuaNjTNTBDHbGGGgcqQkzVtcXX66rTfxWCRpgKd4ef2DY_h4O0SFkioHulskEmiEt03PyZCzfgBd_znNy8_7d183H6urzh0-bi6vKKlXPlRmEcsNoe1E71Y41l81oeikZqyUzHRfKGlmrruGtk04OppWdAimsKJ0Jqepz8vbke1iGCZyFcHycPiScTLrT0aD-dxJwp7fxVvd1w9pWFoM3JwObYs4JxnstZ_oIRu_1QzD6CEafwBTxy4fp99K_JMrC5WkBSge3CElnixAsOEylYu0i_k_OL6RLqZ4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bian, Lun ; Li, Zhaoyue ; He, An ; Wu, Biru ; Yang, Hui ; Wu, Yingsong ; Hu, Fang ; Lin, Guanfeng ; Zhang, Deqing</creator><creatorcontrib>Bian, Lun ; Li, Zhaoyue ; He, An ; Wu, Biru ; Yang, Hui ; Wu, Yingsong ; Hu, Fang ; Lin, Guanfeng ; Zhang, Deqing</creatorcontrib><description>The level of anti-SARS-CoV-2 neutralizing antibodies (NAb) is an indispensable reference for evaluating the acquired protective immunity against SARS-CoV-2. Here, we established an ultrabright nanoparticles-based lateral flow immunoassay (LFIA) for one-step rapid semi-quantitative detection of anti-SARS-CoV-2 NAb in vaccinee's serum. Once embedded in polystyrene (PS) nanoparticles, the aggregation-induced emission (AIE) luminogen, AIE490, exhibited ultrabright fluorescence due to the rigidity of PS and severe inhibition of intramolecular motions. The ultrabright AIE490-PS nanoparticle was used as a fluorescent marker of LFIA. Upon optimized conditions including incubation time, concentrations of coated proteins and conjugated nanoparticles, amounts of antigens modified on the surface of nanoparticles, dilution rate of serum samples, and so on, the ultrabright nanoparticles-based LFIA could accurately identify 70 negative samples and 63 positive samples from human serum (p &lt; 0.0001). The intra- and inter-assay precisions of the established method are above 13% and 16%, respectively. The established LFIA has tremendous practical value of generalization as a rapid semi-quantitative detection method of anti-SARS-CoV-2 NAb. Meanwhile, the AIE490-PS nanoparticle is also promising to detect many other analytes by altering the protein on the surface.</description><identifier>ISSN: 0142-9612</identifier><identifier>EISSN: 1878-5905</identifier><identifier>DOI: 10.1016/j.biomaterials.2022.121694</identifier><identifier>PMID: 35977850</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Aggregation-induced emission ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 - diagnosis ; Humans ; Immunoassay - methods ; Lateral flow immunoassay ; Nanoparticles ; Neutralizing antibody ; SARS-CoV-2</subject><ispartof>Biomaterials, 2022-09, Vol.288, p.121694-121694, Article 121694</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><rights>2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c553t-ab25dbfc923d57f3146fa94400340a8125ca4358617d4d4ba7485e42c21012453</citedby><cites>FETCH-LOGICAL-c553t-ab25dbfc923d57f3146fa94400340a8125ca4358617d4d4ba7485e42c21012453</cites><orcidid>0000-0001-5180-4963 ; 0000-0002-1150-9625</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0142961222003349$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35977850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bian, Lun</creatorcontrib><creatorcontrib>Li, Zhaoyue</creatorcontrib><creatorcontrib>He, An</creatorcontrib><creatorcontrib>Wu, Biru</creatorcontrib><creatorcontrib>Yang, Hui</creatorcontrib><creatorcontrib>Wu, Yingsong</creatorcontrib><creatorcontrib>Hu, Fang</creatorcontrib><creatorcontrib>Lin, Guanfeng</creatorcontrib><creatorcontrib>Zhang, Deqing</creatorcontrib><title>Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum</title><title>Biomaterials</title><addtitle>Biomaterials</addtitle><description>The level of anti-SARS-CoV-2 neutralizing antibodies (NAb) is an indispensable reference for evaluating the acquired protective immunity against SARS-CoV-2. Here, we established an ultrabright nanoparticles-based lateral flow immunoassay (LFIA) for one-step rapid semi-quantitative detection of anti-SARS-CoV-2 NAb in vaccinee's serum. Once embedded in polystyrene (PS) nanoparticles, the aggregation-induced emission (AIE) luminogen, AIE490, exhibited ultrabright fluorescence due to the rigidity of PS and severe inhibition of intramolecular motions. The ultrabright AIE490-PS nanoparticle was used as a fluorescent marker of LFIA. Upon optimized conditions including incubation time, concentrations of coated proteins and conjugated nanoparticles, amounts of antigens modified on the surface of nanoparticles, dilution rate of serum samples, and so on, the ultrabright nanoparticles-based LFIA could accurately identify 70 negative samples and 63 positive samples from human serum (p &lt; 0.0001). The intra- and inter-assay precisions of the established method are above 13% and 16%, respectively. The established LFIA has tremendous practical value of generalization as a rapid semi-quantitative detection method of anti-SARS-CoV-2 NAb. Meanwhile, the AIE490-PS nanoparticle is also promising to detect many other analytes by altering the protein on the surface.</description><subject>Aggregation-induced emission</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>COVID-19 - diagnosis</subject><subject>Humans</subject><subject>Immunoassay - methods</subject><subject>Lateral flow immunoassay</subject><subject>Nanoparticles</subject><subject>Neutralizing antibody</subject><subject>SARS-CoV-2</subject><issn>0142-9612</issn><issn>1878-5905</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUuLFDEUhYMoTjv6FyS4rzZJJfVwIQw9vmBAcBy3IZXc6r5NKmmSqpFx5z83besw7lyFcO85JzkfIa84W3PGm9f79YBxMjMkND6vBRNizQVvevmIrHjXdpXqmXpMVoxLUfUNF2fkWc57Vu5MiqfkrFZ923aKrcjPGz8nMyTc7mYaTIgHk2a0HipvBvDgqD8GGU9HH79TnKYlRJOzuaNjTNTBDHbGGGgcqQkzVtcXX66rTfxWCRpgKd4ef2DY_h4O0SFkioHulskEmiEt03PyZCzfgBd_znNy8_7d183H6urzh0-bi6vKKlXPlRmEcsNoe1E71Y41l81oeikZqyUzHRfKGlmrruGtk04OppWdAimsKJ0Jqepz8vbke1iGCZyFcHycPiScTLrT0aD-dxJwp7fxVvd1w9pWFoM3JwObYs4JxnstZ_oIRu_1QzD6CEafwBTxy4fp99K_JMrC5WkBSge3CElnixAsOEylYu0i_k_OL6RLqZ4</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Bian, Lun</creator><creator>Li, Zhaoyue</creator><creator>He, An</creator><creator>Wu, Biru</creator><creator>Yang, Hui</creator><creator>Wu, Yingsong</creator><creator>Hu, Fang</creator><creator>Lin, Guanfeng</creator><creator>Zhang, Deqing</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5180-4963</orcidid><orcidid>https://orcid.org/0000-0002-1150-9625</orcidid></search><sort><creationdate>20220901</creationdate><title>Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum</title><author>Bian, Lun ; Li, Zhaoyue ; He, An ; Wu, Biru ; Yang, Hui ; Wu, Yingsong ; Hu, Fang ; Lin, Guanfeng ; Zhang, Deqing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c553t-ab25dbfc923d57f3146fa94400340a8125ca4358617d4d4ba7485e42c21012453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aggregation-induced emission</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>COVID-19 - diagnosis</topic><topic>Humans</topic><topic>Immunoassay - methods</topic><topic>Lateral flow immunoassay</topic><topic>Nanoparticles</topic><topic>Neutralizing antibody</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bian, Lun</creatorcontrib><creatorcontrib>Li, Zhaoyue</creatorcontrib><creatorcontrib>He, An</creatorcontrib><creatorcontrib>Wu, Biru</creatorcontrib><creatorcontrib>Yang, Hui</creatorcontrib><creatorcontrib>Wu, Yingsong</creatorcontrib><creatorcontrib>Hu, Fang</creatorcontrib><creatorcontrib>Lin, Guanfeng</creatorcontrib><creatorcontrib>Zhang, Deqing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomaterials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bian, Lun</au><au>Li, Zhaoyue</au><au>He, An</au><au>Wu, Biru</au><au>Yang, Hui</au><au>Wu, Yingsong</au><au>Hu, Fang</au><au>Lin, Guanfeng</au><au>Zhang, Deqing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum</atitle><jtitle>Biomaterials</jtitle><addtitle>Biomaterials</addtitle><date>2022-09-01</date><risdate>2022</risdate><volume>288</volume><spage>121694</spage><epage>121694</epage><pages>121694-121694</pages><artnum>121694</artnum><issn>0142-9612</issn><eissn>1878-5905</eissn><abstract>The level of anti-SARS-CoV-2 neutralizing antibodies (NAb) is an indispensable reference for evaluating the acquired protective immunity against SARS-CoV-2. Here, we established an ultrabright nanoparticles-based lateral flow immunoassay (LFIA) for one-step rapid semi-quantitative detection of anti-SARS-CoV-2 NAb in vaccinee's serum. Once embedded in polystyrene (PS) nanoparticles, the aggregation-induced emission (AIE) luminogen, AIE490, exhibited ultrabright fluorescence due to the rigidity of PS and severe inhibition of intramolecular motions. The ultrabright AIE490-PS nanoparticle was used as a fluorescent marker of LFIA. Upon optimized conditions including incubation time, concentrations of coated proteins and conjugated nanoparticles, amounts of antigens modified on the surface of nanoparticles, dilution rate of serum samples, and so on, the ultrabright nanoparticles-based LFIA could accurately identify 70 negative samples and 63 positive samples from human serum (p &lt; 0.0001). The intra- and inter-assay precisions of the established method are above 13% and 16%, respectively. The established LFIA has tremendous practical value of generalization as a rapid semi-quantitative detection method of anti-SARS-CoV-2 NAb. Meanwhile, the AIE490-PS nanoparticle is also promising to detect many other analytes by altering the protein on the surface.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>35977850</pmid><doi>10.1016/j.biomaterials.2022.121694</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5180-4963</orcidid><orcidid>https://orcid.org/0000-0002-1150-9625</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0142-9612
ispartof Biomaterials, 2022-09, Vol.288, p.121694-121694, Article 121694
issn 0142-9612
1878-5905
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9360774
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aggregation-induced emission
Antibodies, Neutralizing
Antibodies, Viral
COVID-19 - diagnosis
Humans
Immunoassay - methods
Lateral flow immunoassay
Nanoparticles
Neutralizing antibody
SARS-CoV-2
title Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T10%3A43%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ultrabright%20nanoparticle-labeled%20lateral%20flow%20immunoassay%20for%20detection%20of%20anti-SARS-CoV-2%20neutralizing%20antibodies%20in%20human%20serum&rft.jtitle=Biomaterials&rft.au=Bian,%20Lun&rft.date=2022-09-01&rft.volume=288&rft.spage=121694&rft.epage=121694&rft.pages=121694-121694&rft.artnum=121694&rft.issn=0142-9612&rft.eissn=1878-5905&rft_id=info:doi/10.1016/j.biomaterials.2022.121694&rft_dat=%3Cpubmed_cross%3E35977850%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35977850&rft_els_id=S0142961222003349&rfr_iscdi=true